Jurado SF, Peralta CG, Morales SM, Rodríguez AM, Peralta PML

Idioma: Español
Referencias bibliográficas: 34
Paginas: 50-55
Archivo PDF: 186.64 Kb.

RESUMEN

La psoriasis, en la actualidad, se considera una enfermedad sistémica, autoinmune, que condiciona un microambiente inflamatorio mediado por diversas citocinas, principalmente TNF-α, IL-20 e IL-17. La piel es el principal órgano de choque, lo que induce una queratinopoyesis acelerada que culmina en la expresión clínica característica. Por su carácter sistémico, se ha observado que los pacientes con esta dermatosis tienen mayor prevalencia de comorbilidades, entre ellas el síndrome metabólico. Un metaanálisis demostró que los pacientes con psoriasis tienen el doble de riesgo para desarrollar síndrome metabólico que la población en general. En la población mexicana no existen estudios que demuestren dicho comportamiento. Objetivo: Determinar la prevalencia de síndrome metabólico en pacientes adultos con psoriasis. Material y métodos: Se reclutaron pacientes con diagnóstico clínico e histológico de psoriasis. Se evaluaron clínicamente y se determinó si tenían síndrome metabólico de acuerdo a los criterios del NCEP ATP III. La extensión y severidad de la psoriasis se evaluó con el Psoriasis Area and Severity Index (PASI). Resultados: Se estudiaron 39 pacientes con psoriasis en placas de la Consulta Externa del Centro Dermatológico «Dr. Ladislao de la Pascua». El 43.5% (IC95%, 28-60%) de los mismos fueron diagnosticados con síndrome metabólico. Al comparar pacientes con y sin síndrome metabólico, se encontraron diferencias estadísticamente significativas en la circunferencia abdominal, nivel de triglicéridos y presión arterial (p ‹ 0.05). Conclusiones: Por el tamaño de muestra y su homogeneidad en relación a las características de la psoriasis no fue posible determinar con precisión la prevalencia del síndrome metabólico en población mexicana. Este estudio servirá de antecedente para estudios epidemiológicos que exploren la asociación entre psoriasis y síndrome metabólico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Griffi ths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet. 2007; 9583: 263-71.

2. Griffi ths CEM. The immunological basis of psoriasis. JEADV. 2003; 17(s2): 1-5.

3. Parisi R, Symmons D, Griffi ths C, Ashcroft D. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. J Invest Dermatol. 2013;133:377-385.

4. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Kremers HM. Trends in incidence of adult-onset psoriasis overt three decades: a population-based study. J Am Acad Dermatol. 2009;60:394-401.

5. Gelfand JM, Weinstein R, Porter SB et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537-41.

6. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmunity. 2010;34:J314-J321.

7. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in people with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013. doi: 10.1038/jid.2013.149.

8. Khalid U, Hansen PR, Gislason GH, Lindhardsen J, Kristensen SL, Winther SA, Skov L, Torp-Pedersen C, Ahlehoff O. Psoriasis and New-Onset Diabetes Mellitus: A Danish nationwide cohort study. Diabetes Care. 2013;36:2402-7. doi: 10.2337/dc12-2330.

9. Armstrong AW, Harskamp CT, Armstrong EJ et al. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68:654-662.

10. Grundy SM, Brewer B, Cleeman JI et al. Defi nition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/ American Heart Association Conference on scientifi c issues related to defi nition. Circulation. 2004;109:433-438.

11. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome. An American Hearth Association/National Heart, Lung, and Blood Institute Scientifi c Statement. Circulation. 2005;112:2735-2752.

12. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide defi nition. Lancet. 2005;366:1059-1062.

13. Ford ES. Prevalence of the metabolic síndrome defi ned by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28:2745-2749.

14. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.

15. Rojas R, Aguilar-Salinas CA, Jiménez-Corona A et al. Metabolic syndrome in Mexican adults. Results from the National Health and Nutrition Survey 2006. Salud Pública Mex. 2010;52(supl 1):S11-S18.

16. Mallbris L, Ritchlin CT, Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep. 2006;8:355-363.

17. Sommer D, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006; 298:321-328.

18. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68:654-662.

19. Nickoloff BJ, Karabin GD, Barker JN et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol. 1991;138:129-40.

20. Chen YJ, Wu CY, Shen JL et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144: 1571-1575.

21. Márquez-Sandoval F, Macedo-Ojeda G, Viramontes-Hörner D et al. The prevalence of metabolic syndrome in Latin America: a systematic review. Public Health Nutrition. 2011;14:1702-1713.

22. Aguilar-Salinas CA, Rojas R, GómezPérez FJ et al. High prevalence of metabolic syndrome in Mexico. Arch Med Res. 2004;35:76-81.

23. Gisondi P, Tessari G, Conti A et al. Prevalence of metabolic syndrome in patients whit psoriasis: a hospital-based case-control study. Br J Dermatol. 2007; 157: 68-73.

24. Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol venereal Leprol. 2010; 76:662-5.

25. Love TJ, Qureshi AA, Karlson EW et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011;147:419-424.

26. Chen YJ, Wu CY, Shen JL et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144:1571-1575.

27. Al-Mutiari N, Al-Farag S, Al-Mutiari A et al. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol. 2010;37:146-55.

28. Lisi D, Macaione F, Corrado E et al. Cardiovascular risk profi le of patients with psoriasis. Recenti Prog Med. 2013; 104:102-105.

29. Mebazaa A, El-Asmi M, Zidi W et al. Metabolic syndrome in Tunisian psoriatic patients: prevalence and determinants. JEADV. 2011;25:705-709.

30. Langan SM, Seminara NM, Shin DB et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 pt 1):556-562.

31. Topic I, Simic D. Prevalence of metabolic syndrome in patients with psoriasis at Mostar Clinical Hospital. Acta Clin Croat. 2013;52:53-58.

32. Madanagobalane S, Anandan S. Prevalence of metabolicsyndrome in South Indian patients with psoriasis vulgaris and the relation between disease severity and metabolicsyndrome: a hospital-based case-control study. Indian J Dermatol. 2012;57:353:357.

33. Zindaci I, Albayrak O, Kavala M et al. Prevalence of metabolic syndrome in patients with psoriasis. Scientifi c World Journal. 2012;:312463. doi: 10.1100/2012/312463.

34. Augustin M, Reich K, Glaeske G et al. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90:147-151.